Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome
| Autor: | Nikita Mehra, Sridevi Velusamy, Jayachandran Perumal Kalaiarasi, Trivadi S. Ganesan, Arvind Krishnamurthy, Geetha Senguttuvan, Manikandan Dhanushkodi, Indhuja Muthiah Vaikundaraja, M. S. Rao, Tenali Gnana Sagar, Rama Ranganathan, Selvaluxmy Ganesarajah, Venkatraman Radhakrishnan, Balasubramanian Ananthi, Arun Kumar Rajan, Priya Iyer, Siva Sree Kesana, Shirley Sundersingh, Hemanth Raj, Gangothri Selvarajan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment lcsh:RC254-282 Metastasis hormone positive Breast cancer Drug Guides Internal medicine medicine Lymph node advanced breast cancer Univariate analysis Chemotherapy Fulvestrant fulvestrant Oncology (nursing) business.industry Cancer Retrospective cohort study medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ophthalmology medicine.anatomical_structure business medicine.drug |
| Zdroj: | Cancer Research, Statistics, and Treatment, Vol 3, Iss 2, Pp 275-280 (2020) |
| ISSN: | 2590-3225 2590-3233 |
| Popis: | Background: Fulvestrant has been shown to improve survival in hormone-positive, HER2-negative advanced breast cancer (ABC). There is no study on fulvestrant from India. Objectives: This study was done to assess the prognostic factors and outcome of patients with ABC treated with fulvestrant. Materials and Methods: This was a retrospective study from the case records of patients who received fulvestrant for hormone receptor (HR)-positive breast cancer from May 2011 to July 2019. Results: A total of 37 women were included in this analysis, with a median follow-up of 9 months. The median age was 63 years. The Eastern Cooperative Oncology Group performance status (ECOG PS) was 0–2 (78%) and 3–4 (22%). The sites of metastasis were bone (59%), lung (43%), liver (32%), lymph node (24%), and bone only (20%). Patients with visceral metastasis and visceral crisis constituted 60% and 13%, respectively. The median number of lines of prior systemic therapy for metastatic disease was 2 (range, 0–6). The dose of fulvestrant used was 500 mg in 76% and 250 mg in 24%. There were no Grade 3 or 4 toxicities due to fulvestrant. The median progression-free survival and overall survival were 10 months (95% confidence interval [CI], 4–15.9 months) and 21 months (95% CI, 8.9–33.1 months), respectively. Univariate analysis showed that patients with ECOG PS 3–4 had a worse survival as compared to patients with PS 0–2. Conclusion: This is the first study on the outcomes of fulvestrant in advanced breast cancer from India. Fulvestrant is safe, well-tolerated, and effective in patients with hormone-positive ABC. Fulvestrant can be recommended even in heavily pretreated HR-positive advanced breast cancer and in those with a poor general condition (ECOG PS 3 or 4) who are ineligible for chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|